{
    "clinical_study": {
        "@rank": "65361", 
        "arm_group": [
            {
                "arm_group_label": "Cohort A: Nivolumab followed by Ipilimumab", 
                "arm_group_type": "Experimental", 
                "description": "Nivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period  for a maximum of 2 years from 1st study treatment in Induction Period 1\nIpilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period"
            }, 
            {
                "arm_group_label": "Cohort B: Ipilimumab followed by Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Ipilimumab 3 mg/kg solution intravenously every 3 weeks up to 4 doses in Induction period\nNivolumab 3 mg/kg solution intravenously every 2 weeks up to 6 doses in Induction period and 3 mg/kg solution intravenously every 2 weeks until disease progression, unacceptable toxicity, or withdrawal of consent in Continuation period for a maximum of 2 years from 1st study treatment in Induction Period 1"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of a sequential combination\n      therapy of Nivolumab and Ipilimumab"
        }, 
        "brief_title": "Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced or Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Histologically confirmed unresectable Stage III or IV melanoma\n\n          -  Treatment-naive or experienced disease recurrence or progression during or after one\n             prior systemic regimen for advanced disease\n\n          -  Measurable disease by Computed Tomography/Magnetic resonance imaging (CT/MRI) per\n             Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\n          -  Known BRAF V600 mutation status or consent to BRAF V600 mutation testing\n\n          -  Sufficient tumor tissue accessible for baseline and post-treatment biopsies.\n\n        Exclusion Criteria:\n\n          -  Active central nervous system (CNS) metastases\n\n          -  Carcinomatous meningitis\n\n          -  Active, known or suspected autoimmune disease\n\n          -  Condition requiring systemic treatment with either corticosteroids (>10 mg daily\n             prednisone equivalent) or other immunosuppressive medications within 14 days of\n             randomization\n\n          -  Prior therapy with anti-Programmed Death-1 (PD1), anti-Programmed Death-Ligand 1\n             (PD-L1), anti-PD-L2, anti-CD137, or anti-CTLA-4 (cytotoxic T lymphocyte antigen 4)\n             antibody\n\n          -  Prior treatment with other immunotherapies\n\n          -  Prior therapy with BRAF inhibitor within 6 weeks of enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783938", 
            "org_study_id": "CA209-064"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort A: Nivolumab followed by Ipilimumab", 
                    "Cohort B: Ipilimumab followed by Nivolumab"
                ], 
                "intervention_name": "Nivolumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-936558"
            }, 
            {
                "arm_group_label": [
                    "Cohort A: Nivolumab followed by Ipilimumab", 
                    "Cohort B: Ipilimumab followed by Nivolumab"
                ], 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": "Yervoy"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Geoffrey Gibney, Site 0004", 
                    "phone": "813-745-4960"
                }, 
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center & Research Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Health Melvin And Bren Simon Cancer Center"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0001", 
                    "phone": "617-632-4503"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0002", 
                    "phone": "617-726-8178"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "F. Stephen Hodi, Site 0003", 
                    "phone": "617-632-9271"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Allentown", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18103"
                    }, 
                    "name": "Lehigh Valley Health Network"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "University Of Pennsylvania"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22908"
                    }, 
                    "name": "University Of Virginia Health System"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of treatment-related grade 3-5 adverse events (AEs) during the induction period", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate is defined as the number of subjects who have a complete response (CR) or partial response (PR) at Week 25 (with confirmation at scheduled scan at Week 33) divided by the total number of randomized subjects", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1), Week 25 and Week 33"
            }, 
            {
                "description": "Progression rate at a specific timepoint is defined as the number of subjects who have Progressive Disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 at that specific timepoint divided by the total number of randomized subjects", 
                "measure": "Progression rates", 
                "safety_issue": "No", 
                "time_frame": "Baseline (Day 1), Week 13 and Week 25"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}